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ABSTRACT  
Chronic myeloid leukaemia (CML) is a kind of cancer that affects the white blood cells and resort to progress slowly through many years. It’s 
occur at any age, but is most common in older (60-65 years) of age. This is a cross sectional study aimed to detect MTHFR gene polymorphism 
(C677T) among Sudanese patients diagnosed with Chronic Myeloid Leukaemia and conducted at the research laboratory of the national center 
of neurological sciences (NCNS), Khartoum, Sudan.50 patients with Chronic Myeloid Leukemia (CML) diagnosed as BCR-ABL positive by RT-
PCR used as a cases and 50 apparently healthy individuals as a control. A 5 ml of blood samples were collected in EDTA anticoagulant container 
for DNA Extraction and white blood cells count, hemoglobin level and platelets count. Genotyping of the MTHFR was carried out using PCR 
technique and the SNP (C677T) confirmed by sequencing a subset of samples. The results were analyzed using bioinformatics tools. The results 
showed; the most affected age group in the patients was 51-60 years followed by 41-50 years which constituted 32% and 30%, respectively. 
The hematological findings revealed that, the mean of TWBCs was 47.4, HB was 11.9 for patients, 7.2 and 14.1 respectively for  control group (P 
= 0.000). PLT was 313.5 for patients and 287.5 for control group (P = 0.187). MTHFR gene was detected in the all patients (198pb) by the PCR, 
Sequence results were aligned with the reference sequence of MTHFR gene, the polymorphic C >T was found to be matched with th e registered 
mutation in NCBI data base. This study provides the first evidence for associations of MTHFR gene polymorphism with the risk of chronic 
myeloid leukemia in Sudanese patients. The C >T genotype of the rs 677 polymorphism in MTHFR gene may have a promoting effect  on chronic 
myeloid leukemia.  
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INTRODUCTION 
Chronic myeloid leukaemia (CML) is a kind of cancer that 
affects the white blood cells and resort to progress slowly 
through many years. It’s occur at any age, but is most 
common in older (60-65 years) of age. It was first recognized 
as a clinical entity by John Hughes Bennett in the mid-1840s. 
It is also known as chronic myelocytic or chronic 
myelogenous leukemia [1]. 
Chronic myeloid leukaemia arises from a translocation 
between the BCR gene on chromosome 22 and the ABL gene 
on chromosome 9. This reciprocal translocation creates the 
Philadelphia chromosome (t 9;22) and the consequent 
formation of a unique BCR-ABL protein product. This 
protein has constitutive kinase activity that drives 
uncontrolled proliferation of hematopoietic stem cells, 
reduced apoptosis and generating genomic instability [2].  
In the early stages CML usually have no symptoms and may 
only be picked up during tests done for other disease. No 
one is born with CML, it occurs when there is an injury to the 
DNA of a single bone marrow cell; scientists do not yet 
understand why the BCR-ABL gene that leads to CML is 
created in some people and not in others. In a small number 
of patients CML is occurred  by exposure to very high doses 
of radiation, such as individuals treated for other cancers, 
like lymphoma.[3,4] 
Incidence of overall leukemia in 2012 to be 351,965 cases 
(4.7 per 100,000). The incidence of overall leukemia in more 
developed regions in 2012 was estimated as 141,274 (7.2 
per 100,000) versus an incidence of 210,691 (3.8 per 
100,000) in less developed regions. Information on CML 
incidence and prevalence is scare, as CML is a rare disease.[5] 
 
 
Osman et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(6):162-168 
ISSN: 2250-1177                                                                                  [163]                                                                                 CODEN (USA): JDDTAO 
Methylene Tetrahydrofolate Reductase (MTHFR) 
A key enzyme in homocysteine (Hcy) and folate metabolism, 
plays a role in DNA methylation and provision of nucleotides 
for DNA synthesis .   MTHFR gene located on the short arm of 
chromosome 1 at 1p36.3. The cDNA sequence of this gene is 
2.2kb long and is composed of 11 exons (103 to 432 bp) [6,7].  
Mutations in the MTHFR gene may result in enzyme 
deficiency, low plasma folate levels and 
hyperhomocysteinemia, a risk factor for coronary and 
peripheral vascular obstructive events and neural tube 
defects. While, under situations of decreased MTHFR 
activity, more MTHFR substrate is available for purine and 
pyrimidine synthesis, which may prevent imbalances of 
nucleotide pools during DNA synthesis and potentially 
oncogenic alterations in DNA methylation [8]. 
There are two common genetic polymorphisms that have 
been shown to decrease the activity of MTHFR, which are 
the C677T mutation at codon 222 in exon 4 and the A1298C 
mutation at codon 429. Hyperhomocysteinemia is a 
consequence of single nucleotide polymorphisms (SNPs) in 
MTHFR 677 C>T that can cause homocysteine levels in the 
blood to increase, usually exceeding 15 μmol/L. MTHFR 677 
C>T is the result of a missense mutation occurring at 
position 222, where alanine is substituted with valine. The 
mutation results in a thermolabile MTHFR that has lower 
enzyme activity at 37°C, leading to increased total plasma 
homocysteine [10]. Individuals with the MTHFR C677T TT 
genotype have been shown to have 30 percent in vitro 
MTHFR enzyme activity compared with the wild type, 
whereas those with the heterozygous (CT) genotype have 
been found to have 60 percent wild-type MTHFR enzyme 
activity [9]. 
The etiology of most types of leukemia remains unknown,  
leukemias commonly originate as a result of DNA 
translocations, inversions, or deletions in genes regulating 
blood cell development or homeostasis. Folate deficiency has 
been engaged in increasing the risk of chromosomal 
aberrations because it is associated with uracil miss 
incorporation into DNA. Indeed several studies reported that 
is the correlation between the presence of C677T 
polymorphism of the MTHFR gene and the risk of different 
leukemias. The aim of this study to investigate   MTHFR gene 
polymorphism (C677T) might increase the risk for CML in 
Sudanese patients. 
MATERIAL AND METHODS  
This is study a cross sectional study, conducted at the 
research laboratory of the national center of neurological 
sciences (NCNS), Khartoum, Sudan during the period May 
2019 to July 2019.  Fifty patients diagnosed with CML were 
used as a case and   fifty apparently healthy individuals were 
used as a control. Five ml of blood samples was collected in 
EDTA anticoagulant container for DNA Extraction and HB, 
platelets and white blood cells count. 
The data was collected using pre-designed structural 
questionnaire, the demographic and clinical data concerning 
each participant was obtained from the registry data base 
office and the laboratory data included hematological 
results, Polymerase Chain Reaction findings and sequencing 
results. The study was approved by the ethical committee of 
the National Center for Neurological Sciences.              
White blood cells Count 
WBCs have been analyzed using electrical impedance 
method for cell counting Auto Hematology Analyzer 
(Mindray BC_3200).  
Molecular Analysis 
 DNA extraction and purification: 
Genomic DNA was isolated from peripheral blood leukocytes 
by the standard phenol chloroform extraction method; 10 ml 
of RCLB was added to 2.5 ml of blood then centrifuged for 5 
minutes at 6000 rpm , this step was repeated until a clear 
pallet of white blood cell appeared, the supernatant was 
discarded and 2ml of WCLB, 1 ml  of Guanidine 
Hydrochloride, 300 µl of ammonium acetate and 10 µl of 
proteinase K was  added and  incubated at 37ºC overnight. In 
the next day the mixture was cooled to room temperature 
and 2 ml of pre-chilled chloroform was added, the mixture 
vortex then centrifuges for 5 minutes at 6000 rpm after that, 
the upper layer containing DNA   was collected to a new test 
tube and 10 ml of pre-chilled Absolute Ethanol was added 
and kept at -20ºC for 2 hours.  
After incubation the precipitate of DNA was centrifuged for 
10 minutes at 6000 rpm, after that the supernatant 
discharges then the pellet was washed in 4 ml of 70% 
ethanol then the pellet centrifuge for 10 minutes at 6000 
rpm, after centrifugation the supernatant   poure off and the 
pallet was left to dry overnight. The DNA is dissolve in 100 µl 
of ddH2O. Then vortex, incubates at 4ºC for 24 hours and 
store at -20ºC till use  
MTHFR gene amplification 
The MTHFR gene was amplified using PCR. The following 
primers sequences were used to obtain the fragment (198 
bp);  
Forwards: 5- TGAAGGAGAAGGTGTCTGCGGGA -3  
Reverse: 5- AGGACGGTGCGGTGAGAGTG-3 
In a PCR test tube, 14.5 μl ddH2O, 4 μl of master mix 
containing (1.5 buffer, nM MgCl2, 200μm of dNTPs and 0.5 
units of Taq polymerase) were added, and then 0.75 μl from 
each primer and 2 μl of genomic DNA were added. The PCR 
was carried out using a commercial thermal cycler (SwiftTM 
MaxPro SWT-MXP-BLC-4). The amplification steps consisted 
of an initial 12 minutes of denaturation at 95 °C, followed by 
35 cycles of denaturation at 95 °C for 30 seconds, the 
primers were  annealed at 60 °C for 30 seconds, then the 
elongation period was 1 minute at 72 °C ,  the final 
elongation was adjusted for 5 minutes at 72 °C.  The PCR 
amplification product was separated on a 3 % agarose gel 
and trans-illuminated with UV light with a 100-base-pair 
ladder. 
Sequencing: 
PCR products was sent for sequencing to Macrogen Europe 
Laboratory and BGI solutions Hong Kong Co. Ltd. 
Respectively.  
SPSS13.0 statistical software (SPSS Inc., USA) was used for 
statistical analysis. 
RESULTS  
In the present study 50 of chronic myeloid leukemia patients 
were included. Among them, 35 were males, while 15 were 
females. In addition, 50 of apparently healthy individuals 
were selected as control group, 43 were males, while 7 were 
femal.  (fig 1). The most affected age group in the patients 
was 51-60 years followed by 41-50 years which constituted 
32% and 30%, respectively ( Table 1).   
The hematological findings revealed that, the mean of 
TWBCs was 47.4, HB was 11.9 for patients, 7.2 and 14.1 
respectively for control group (P = 0.000) ) (table 3).  PLT 
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was 313.5 for patients  and 287.5 for control group (P = 
0.187) (table 3).  
In the present study 198 bp of MTHFR gene was detected 
with gel electrophoresis after PCR (Figure 4). Thereafter, 
198 bp of MTHFR gene was sequenced using Sanger 
sequencing methods.  
Sequence results were aligned with the reference sequence 
of MTHFR gene (accession number NG 013351.1 in NCBI) 
(Figure 5). In this study the polymorphic C >T was found to 
be matched with the registered mutation in NCBI data base 
(Figure 6). 
Table 1. Age groups of affected patients 
Age groups  Frequency Percent 
Less than 30 3 6.0 
30 – 40 11 22.0 
41 – 50 15 30.0 
51 – 60 16 32.0 
More than 60 5 10.0 
Total 50 100.0 
 
 
Fig (1): Frequency of gender among study population
 
 
Table (2): Descriptive Statistics of variables 
Variables  Study population N Minimum Maximum Mean Std. Deviation 
Population  CML patients  50 22 70 47.4 10.3 
Control    50 18 58 37.9 12.9 
TWBCs (×109/l) CML patients 50 5.4 237.0 71.1 62.1 
Control    4.2 10.9 7.2 2.2 4.2 
Hemoglobin (g/dl) CML patients 50 7.0 15.5 11.9 1.9 
Control    12.5 15.7 14.2 0.8 12.5 
Platelet count 
(×109/l) 
CML patients 80 490 313.5 103.1 80 
Control    155 460 287.5 91.9 155 
 
 
Table (3): Comparison white cells Count, hemoglobin and Platelet count between CML patients and controls. 
Parameters Population group  
(Mean ± SD)  
P. value 
CML patients  (n=50) Normal individual  (n=50) 
TWBCs (×109/l) 71.1 ± 62.1 7.2 ± 2.1 0.000 
Hemoglobin g\dl 11.9 ± 1.9 14.1 ± 0.9 0.000 
Platelet count (×109/l) 313.5 ± 103.1 287.5 ± 91.9 0.187 
  
 
Table (4): Comparison of age, white cells Count, hemoglobin and Platelet count among gender of CML patients 
Parameters Gender  
(Mean ± SD)  
P. value 
Male   (n=35) Female  (n=15) 
TWBCs (×109/l) 78.9 ± 66.7 52.7 ± 46.6 0.173 
Hemoglobin (g\dl) 11.7 ± 2.0 12.2 ± 1.8 0.429 
Platelet count (×109/l) 299.5 ± 99.7 346.4 ± 106.9 0.142 
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Table (5): Correlation between white cells Count and Platelet count 
Correlations 
  TWBCs Platelet count 
TWBCs Pearson Correlation 1 -.089 
Sig. (2-tailed)  .540 
N 50 50 
Platelet count Pearson Correlation -.089 1 
Sig. (2-tailed) .540  
N 50 50 
 
 
Fig (2): Correlation between white cells Count and Platelet count 
Table (6): Correlation between white cells Count and hemoglobin 
Correlations 
  TWBCs Hemoglobin 
TWBCs Pearson Correlation 1 .076 
Sig. (2-tailed)  .602 
N 50 50 
Hemoglobin Pearson Correlation .076 1 
Sig. (2-tailed) .602  
N 50 50 
 
 
Fig (3) Correlation between white cells Count and hemoglobin 
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Fig(4): Gel electrophoresis for MTHFR gene 
lane 1 (100 bp ladder), lane 2, 3 and 4 (198 bp product of IL-16 gene) 
 
 
Fig (5): MTHFR gene accession number 
 
Fig 6: Multiple sequence alignment using Bio-Edit clustal W for samples with reference gene sequence of MTHFR gene 
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Fig (7):  Results of MTHFR (C677T) among population 
DISCUSSION  
In the present study our results showed the most affected 
population were men and the most affected   age group by 
CML was ranging between 51-60 years. One of the studies 
reported that; most cases of CML occur in adults. From 2007 
to 2011, the median age at diagnosis for CML was 64 years a 
small number of children develop CML.[9] 
The hematological findings of white blood cell count resulted 
that there was significant difference between patients and 
control group, the mean of WBCs was 47.4 for patients (P = 
0.000).Also  there was significant difference between 
patients and control group for the HB level  the mean of HB 
was 11.7  for patients (P = 0.000). The same finding was 
reported by the other study; significantly related to high 
WBC counts at presentation: age<40 years, hemoglobin 
levels<120 g/L, (all P<0.05).[10]  Regarding the platelets 
count our results reveled that; insignificant difference 
between patients and control group, the mean platelets was 
313.5 for patients (P = 0.187). In contrast in the other 
studies; there was significant differences of platelet count 
with (P = 0.005). [10,11] 
Methylenetetrahydrofolate Reductase (MTHFR) is the key 
enzyme in folate metabolism. It Irreversibly reduces 5, 10- 
methylenetetrahydrofolate (5,10-methylene-THF) to 5-
methyl-THF which is the main form of folate in serum that is 
involved in amino acid synthesis where it remethylates 
homocysteine into methionine at the expense of nucleotide 
synthesis. [12] There are two common genetic polymorphisms 
that have been shown to decrease the activity of MTHFR 
which are the C677T mutation at codon 222, and the A1298C 
mutation at codon 429.[13] 
Since the MTHFR gene has an essential role in folate 
metabolism, genetic polymorphisms in this gene could alter 
the susceptibility to different cancers including 
hematological malignancies, as it was shown that an 
appropriate supply of folate is crucial specially for rapidly 
replicating cells such as hematopoietic cells. Indeed, several 
previous studies have noticed a change in cancer risk in 
individuals with mutated MTHFR genotypes. However, only 
a small number of reports have studied the effect of MTHFR 
gene alterations on the risk of developing leukemia. Those 
reports have focused on acute leukemias such as acute 
lymphoblastic leukemia (ALL), and acute myelogenous 
leukemia (AML), where they described a lower risk of ALL in 
individuals with mutated MTHFR alleles, but not in the case 
of AML.[14] Only very few studies addressed the association 
between MTHFR genotypes and the risk of CML.   
In this study, the association between MTHFR 
polymorphism C677T and the risk of CML is thoroughly 
investigated in the Sudanese population for the first time. 
The results of this study showed that all the patients were 
having CT allele. One of the studies reported that; the 
difference in frequency of the heterozygous C677T CT 
genotype between CML patients and controls was not 
statistically significant [15]. Another study agreed that the 
C677T variants had no effect [16]. A study done in Jordanian 
population reported that; the present study demonstrates a 
clear association between mutated MTHFR genotypes and 
an increased risk of CML [17]. 
CONCLUSION  
This study provides the first evidence for associations of 
MTHFR gene polymorphism with the risk of chronic myeloid 
leukemia in Sudanese patients. The CT genotype of the rs 
677 polymorphism in MTHFR gene may have a promoting 
effect on chronic myeloid leukemia.  
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